MCRB insider buying and SEC filings, explained
Seres Therapeutics, Inc. · CIK 1609809
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
- Former names
- Seres Therapeutics, Inc.; Seres Health, Inc.
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$444
Planned sales (10b5-1)
$54K
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Aug 17, 2026 | Planned (10b5-1) | Kelly Brady (President / COO) sold 64 shares at $4.55 ($291), marked as a 10b5-1 plan trade. Holdings down 1% to 8,679 shares. | SEC filing Filed Aug 18, 2026 |
| Aug 17, 2026 | Planned (10b5-1) | Eric D. Shaff (Director) sold 263 shares at $4.55 ($1K), marked as a 10b5-1 plan trade. Holdings down 2% to 12,499 shares. | SEC filing Filed Aug 18, 2026 |
| Aug 17, 2026 | Planned (10b5-1) | Matthew R Henn (President / COO) sold 81 shares at $4.55 ($369), marked as a 10b5-1 plan trade. Holdings down 1% to 7,995 shares. | SEC filing Filed Aug 18, 2026 |
| Aug 17, 2026 | Planned (10b5-1) | Thomas DesRosier (Chief Legal Officer) sold 82 shares at $4.55 ($373), marked as a 10b5-1 plan trade. Holdings down 1% to 8,117 shares. | SEC filing Filed Aug 18, 2026 |
| May 18, 2026 | Planned (10b5-1) | Eric D. Shaff (Director) sold 259 shares at $7.53 ($2K), marked as a 10b5-1 plan trade. Holdings down 2% to 12,040 shares. | SEC filing Filed May 19, 2026 |
| May 18, 2026 | Sale | Kelly Brady (President / COO) sold 59 shares at $7.53 ($444). Holdings down 1% to 8,562 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 19, 2026 |
| May 18, 2026 | Planned (10b5-1) | Thomas DesRosier (Chief Legal Officer) sold 79 shares at $7.53 ($595), marked as a 10b5-1 plan trade. Holdings down 1% to 7,954 shares. | SEC filing Filed May 19, 2026 |
| May 18, 2026 | Planned (10b5-1) | Matthew R Henn (Chief Scientific Officer) sold 77 shares at $7.53 ($580), marked as a 10b5-1 plan trade. Holdings down 1% to 7,838 shares. | SEC filing Filed May 19, 2026 |
| Feb 15, 2026 | Planned (10b5-1) | Teresa L. Young (Chief Commercial & Strategy Officer) sold 75 shares at $8.47 ($635), marked as a 10b5-1 plan trade. Holdings down 1% to 8,557 shares. | SEC filing Filed Feb 18, 2026 |
| Feb 15, 2026 | Planned (10b5-1) | Eric D. Shaff (Director) sold 259 shares at $8.47 ($2K), marked as a 10b5-1 plan trade. Holdings down 2% to 11,577 shares. | SEC filing Filed Feb 18, 2026 |
| Feb 15, 2026 | Planned (10b5-1) | Thomas DesRosier (CEO) sold 78 shares at $8.47 ($661), marked as a 10b5-1 plan trade. Holdings down 1% to 7,789 shares. | SEC filing Filed Feb 18, 2026 |
| Feb 15, 2026 | Planned (10b5-1) | Matthew R Henn (Chief Scientific Officer) sold 89 shares at $8.47 ($754), marked as a 10b5-1 plan trade. Holdings down 1% to 7,677 shares. | SEC filing Filed Feb 18, 2026 |
| Nov 15, 2025 | Planned (10b5-1) | Thomas DesRosier (CEO) sold 76 shares at $17.30 ($1K), marked as a 10b5-1 plan trade. Holdings down 1% to 7,623 shares. | SEC filing Filed Nov 18, 2025 |
| Nov 15, 2025 | Planned (10b5-1) | Teresa L. Young (Chief Commercial & Strategy Officer) sold 1,042 shares at $17.30 ($18K), marked as a 10b5-1 plan trade. Holdings down 11% to 8,401 shares. | SEC filing Filed Nov 18, 2025 |
| Nov 15, 2025 | Planned (10b5-1) | Eric D. Shaff (Director) sold 217 shares at $17.30 ($4K), marked as a 10b5-1 plan trade. Holdings down 2% to 11,113 shares. | SEC filing Filed Nov 18, 2025 |
| Nov 15, 2025 | Planned (10b5-1) | Matthew R Henn (Chief Scientific Officer) sold 1,257 shares at $17.30 ($22K), marked as a 10b5-1 plan trade. Holdings down 14% to 7,527 shares. | SEC filing Filed Nov 18, 2025 |
36 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow MCRB in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.